image credit: Adobe Stock

Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug

June 16, 2023

Bispecific antibodies like Columvi are dual targeting, designed to bind to two cellular proteins, rather than one. In recent years, these types of drugs have won approval for use in multiple types of tumors, eye diseases and hemophilia.

Development has been fastest in blood cancer, where bispecifics are often made to latch onto proteins found on cancer cells with one arm, while hooking immune cell proteins with the other. In some cases, they’re seen as more accessible alternatives to CAR-T cell therapies.

Read More on Biopharma Dive